English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Intestinal inflammation, especially chronic (such as inflammatory bowel disease [IBD]), is an indispensable participant in the colonic neoplastic process, fostering the proliferation, survival, and migration of colonic tumor cells. Molecularly targeted therapeutics (e.g. anti-TNF-α agents) that exploit the targets involved in the pathophysiology of inflammatory responses in IBD are the most potent drugs currently available to treat IBD, which may also present anti-colon cancer effects. Unfortunately, most of these drugs were administered systemically in a high dose, and their use is limited by severe side effects. There is an unmet need for a targeted carrier system capable of delivering drugs specifically and effectively to inflamed colonic regions over a prolonged period. Such a system could significantly reduce drug dosage and side effects that limit existing treatments. The goal of the present study is to engineer natural “nanoliposomes” from the lipids of ginger-derived-nanoparticles and load with an anti-inflammatory drug candidate (M13), test its anticancer activity, and evaluate its safety. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay demonstrated that M13, a stable metabolite from 6-Shogaol as demonstrated by the incubation with intestinal microsomes, was more cytotoxic against cancerous intestinal cells (e.g. HCT-116, Caco-2/BBe, and human colon cancer stem cell) than normal intestinal cells (e.g. HIEC-6, FHC, and human colon stem cell). The results suggested that M13 has more a better ability to specifically target cancerous intestinal cells over normal intestinal cells. Protein point hybridization data showed that nanoliposomes-loaded M13 decreased the expression levels of proteins involved in colon cancer progressions such as Survivin, EGFR, and BCL-x in colon cancer cells. Further, orally administered nanoliposomes-loaded M13 presented potent wound-healing/anti-inflammatory effects in the DSS-induced mouse model of colitis and anti-cancer effects in the AOM/DSS-induced colon cancer model. We also demonstrated that nanoliposomes-loaded M13 treatment did not affect blood. In addition, we examined the anti-inflammatory activity of M13 on active ulcerative mucosal biopsies (Reprocell tissue protocol TPS-008) from a patient (42-year-old white male) undergoing therapeutic resection for ulcerative colitis. The results of the RT2 Profiler PCR Array demonstrated that M13 had very potent anti-inflammatory activity and reduced the expression levels of the pro-inflammatory cytokines involved in IBD, including TNF-α, IL-1β, IL-6, and IL-23A, in the M13-treated human ulcerative biopsies compared to the untreated controls. Our proposed targeted therapy using nanoliposomes that deliver M13 to the colon might be used to treat ulcerative colitis and colitis-associated cancer without causing any side effects.

ORAL ADMINISTRATION OF NANOLIPOSOMES LOADED M13 MAY TREAT ULCERATIVE COLITIS AND COLITIS-ASSOCIATED CANCER WITHOUT CAUSING ANY SIDE EFFECTS